domingo, 30 de agosto de 2026

FDA approves Roivant therapy for rare autoimmune disease Drug provides a new option for patients — and a new kind of opportunity for the biotech company

https://www.statnews.com/2026/08/27/fda-approves-roivant-therapy-for-rare-autoimmune-disease/ By Adam FeuersteinAug. 27, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

No hay comentarios:

Publicar un comentario